[{"id":"51bfec9e-786f-4114-83f4-e740501ef39e","acronym":"KEYNOTE-E34","url":"https://clinicaltrials.gov/study/NCT05784688","created_at":"2023-03-27T20:03:27.380Z","updated_at":"2025-02-25T14:09:34.861Z","phase":"Phase 1/2","brief_title":"Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05784688 - KEYNOTE-E34","lead_sponsor":"TiumBio Co., Ltd.","biomarkers":" EGFR • KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • HER-2 amplification • BRAF V600 • BRAF wild-type","tags":["EGFR • KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • HER-2 amplification • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • tosposertib (NCE 401)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 03/10/2023","start_date":" 03/10/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-02-17"},{"id":"2fbb65a4-a780-422e-b302-4dd9315ffcc1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05145569","created_at":"2024-06-01T04:17:55.472Z","updated_at":"2024-07-02T16:35:00.527Z","phase":"Phase 2","brief_title":"Antitumor Activity of Neoadjuvant Chemotherapy With or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer","source_id_and_acronym":"NCT05145569","lead_sponsor":"Haider Mahdi","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • HCW9218"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 05/10/2024","start_date":" 05/10/2024","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 01/31/2028","study_completion_date":" 01/31/2028","last_update_posted":"2024-05-29"},{"id":"4c05af61-5d05-4c37-bd6c-572d69e5c509","acronym":"BETA-PRIME","url":"https://clinicaltrials.gov/study/NCT04673942","created_at":"2024-02-16T15:19:06.027Z","updated_at":"2024-07-02T16:35:04.617Z","phase":"Phase 2","brief_title":"A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors","source_id_and_acronym":"NCT04673942 - BETA-PRIME","lead_sponsor":"EpicentRx, Inc.","biomarkers":" TGFB1","pipe":"","alterations":" ","tags":["TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AIM-001"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 03/29/2021","start_date":" 03/29/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-05-09"},{"id":"de38c659-13cf-45fe-9cef-d1ffb1fba21f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02688712","created_at":"2021-01-18T13:06:46.618Z","updated_at":"2024-07-02T16:35:22.277Z","phase":"Phase 2","brief_title":"ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer","source_id_and_acronym":"NCT02688712","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • capecitabine • galunisertib (LY2157299) • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/24/2016","start_date":" 03/24/2016","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-01-25"},{"id":"701870c6-cbbc-4e3e-a80e-76fa0fa4ed41","acronym":"DRAGON","url":"https://clinicaltrials.gov/study/NCT04291079","created_at":"2021-01-18T20:49:29.388Z","updated_at":"2024-07-02T16:35:23.706Z","phase":"Phase 1","brief_title":"SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)","source_id_and_acronym":"NCT04291079 - DRAGON","lead_sponsor":"Scholar Rock, Inc.","biomarkers":" EGFR • ALK","pipe":"","alterations":" ","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e linavonkibart (SRK-181)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 04/23/2020","start_date":" 04/23/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-11"},{"id":"678d8ba2-1946-41e3-baad-604dd5949706","acronym":"","url":"https://clinicaltrials.gov/study/NCT02672475","created_at":"2021-01-18T13:01:45.641Z","updated_at":"2024-07-02T16:35:28.392Z","phase":"Phase 1","brief_title":"Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer","source_id_and_acronym":"NCT02672475","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • HER-2 expression • ER negative • PGR expression • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression • ER negative • PGR expression • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • galunisertib (LY2157299)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 04/01/2021","primary_completion_date":" 04/01/2021","study_txt":" Completion: 08/01/2023","study_completion_date":" 08/01/2023","last_update_posted":"2023-11-22"},{"id":"36d05294-4a12-477b-b97b-7d1705c42e3a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03073525","created_at":"2021-01-18T15:08:28.985Z","updated_at":"2024-07-02T16:35:51.417Z","phase":"Phase 2","brief_title":"A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers","source_id_and_acronym":"NCT03073525","lead_sponsor":"Gradalis, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Vigil (gemogenovatucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 05/31/2017","start_date":" 05/31/2017","primary_txt":" Primary completion: 05/22/2019","primary_completion_date":" 05/22/2019","study_txt":" Completion: 05/18/2022","study_completion_date":" 05/18/2022","last_update_posted":"2023-04-05"},{"id":"b6f71eec-7809-4305-ba8a-5033e44f0df2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05228600","created_at":"2022-02-12T17:48:00.959Z","updated_at":"2024-07-02T16:36:10.084Z","phase":"Phase 1","brief_title":"YL-13027 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05228600","lead_sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YL-13027"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 05/17/2022","start_date":" 05/17/2022","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-05-20"},{"id":"5bc6f575-e47f-45a8-9b3d-701f5f0db4f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02906397","created_at":"2021-01-29T07:13:11.508Z","updated_at":"2024-07-02T16:36:14.684Z","phase":"Phase 1","brief_title":"Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)","source_id_and_acronym":"NCT02906397","lead_sponsor":"Abramson Cancer Center of the University of Pennsylvania","biomarkers":" CD4 • TGFB1","pipe":"","alterations":" ","tags":["CD4 • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e galunisertib (LY2157299)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 03/30/2017","start_date":" 03/30/2017","primary_txt":" Primary completion: 07/21/2021","primary_completion_date":" 07/21/2021","study_txt":" Completion: 07/21/2021","study_completion_date":" 07/21/2021","last_update_posted":"2022-03-25"},{"id":"71ce3557-7186-4552-8aeb-83c3fb94cbdc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01061840","created_at":"2021-01-18T04:10:59.745Z","updated_at":"2024-07-02T16:36:15.390Z","phase":"Phase 1","brief_title":"Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer","source_id_and_acronym":"NCT01061840","lead_sponsor":"Gradalis, Inc.","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vigil (gemogenovatucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 12/01/2009","start_date":" 12/01/2009","primary_txt":" Primary completion: 12/06/2018","primary_completion_date":" 12/06/2018","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2022-03-15"},{"id":"e1ab9724-6bf9-4432-b02c-3c4942410528","acronym":"","url":"https://clinicaltrials.gov/study/NCT02947165","created_at":"2021-01-18T14:28:07.532Z","updated_at":"2024-07-02T16:36:17.808Z","phase":"Phase 1","brief_title":"Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.","source_id_and_acronym":"NCT02947165","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD8","pipe":" | ","alterations":" TILs","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001) • nisevokitug (NIS793)"],"overall_status":"Completed","enrollment":" Enrollment 120","initiation":"Initiation: 04/25/2017","start_date":" 04/25/2017","primary_txt":" Primary completion: 06/18/2021","primary_completion_date":" 06/18/2021","study_txt":" Completion: 06/18/2021","study_completion_date":" 06/18/2021","last_update_posted":"2022-01-31"},{"id":"09e15c9c-e287-4fad-a870-fd5bca457d88","acronym":"","url":"https://clinicaltrials.gov/study/NCT02423343","created_at":"2021-01-18T11:35:30.982Z","updated_at":"2025-02-25T14:35:29.707Z","phase":"Phase 1b/2","brief_title":"A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma","source_id_and_acronym":"NCT02423343","lead_sponsor":"Eli Lilly and Company","biomarkers":" EGFR • ALK • AFP","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK fusion • AFP elevation","tags":["EGFR • ALK • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK fusion • AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • galunisertib (LY2157299)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 12/13/2018","primary_completion_date":" 12/13/2018","study_txt":" Completion: 07/08/2020","study_completion_date":" 07/08/2020","last_update_posted":"2021-09-09"},{"id":"79d3aa36-b552-432f-b11b-b6963dede275","acronym":"","url":"https://clinicaltrials.gov/study/NCT02725489","created_at":"2021-06-23T19:53:40.049Z","updated_at":"2025-02-25T14:57:37.030Z","phase":"Phase 2","brief_title":"Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers","source_id_and_acronym":"NCT02725489","lead_sponsor":"Mary Crowley Medical Research Center","biomarkers":" IFNG","pipe":" | ","alterations":" PD-L1 expression","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Vigil (gemogenovatucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 06/03/2016","start_date":" 06/03/2016","primary_txt":" Primary completion: 12/30/2019","primary_completion_date":" 12/30/2019","study_txt":" Completion: 12/02/2020","study_completion_date":" 12/02/2020","last_update_posted":"2021-01-27"},{"id":"be737b18-0f8e-4837-8699-13ec5fb6d2ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT01246986","created_at":"2021-01-17T17:47:45.498Z","updated_at":"2024-07-02T16:36:36.161Z","phase":"Phase 2","brief_title":"A Study of LY2157299 in Participants With Hepatocellular Carcinoma","source_id_and_acronym":"NCT01246986","lead_sponsor":"Eli Lilly and Company","biomarkers":" AFP • TGFB1","pipe":"","alterations":" ","tags":["AFP • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • Cyramza (ramucirumab) • galunisertib (LY2157299)"],"overall_status":"Completed","enrollment":" Enrollment 204","initiation":"Initiation: 03/30/2011","start_date":" 03/30/2011","primary_txt":" Primary completion: 06/06/2019","primary_completion_date":" 06/06/2019","study_txt":" Completion: 12/24/2019","study_completion_date":" 12/24/2019","last_update_posted":"2021-01-12"},{"id":"90e3f6c7-8f4e-4efc-8376-ded3912b721b","acronym":"EORTC1615","url":"https://clinicaltrials.gov/study/NCT03470350","created_at":"2021-01-18T17:06:13.499Z","updated_at":"2024-07-02T16:36:57.715Z","phase":"Phase 1/2","brief_title":"Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer","source_id_and_acronym":"NCT03470350 - EORTC1615","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" TGFB1","pipe":"","alterations":" ","tags":["TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Vectibix (panitumumab) • capecitabine • galunisertib (LY2157299)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/24/2018","start_date":" 08/24/2018","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 06/01/2020","study_completion_date":" 06/01/2020","last_update_posted":"2019-07-24"},{"id":"3dd54b28-d3fd-4201-b4d1-d646fcc1df03","acronym":"","url":"https://clinicaltrials.gov/study/NCT01373164","created_at":"2021-01-18T05:37:33.714Z","updated_at":"2024-07-02T16:37:10.720Z","phase":"Phase 1b/2","brief_title":"A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer","source_id_and_acronym":"NCT01373164","lead_sponsor":"Eli Lilly and Company","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • galunisertib (LY2157299)"],"overall_status":"Completed","enrollment":" Enrollment 170","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 11/01/2015","primary_completion_date":" 11/01/2015","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2018-05-16"},{"id":"8b173a76-6028-4f1a-b970-8488f8a9484f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02574533","created_at":"2021-01-18T12:28:37.846Z","updated_at":"2024-07-02T16:37:17.532Z","phase":"Phase 1","brief_title":"Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma","source_id_and_acronym":"NCT02574533","lead_sponsor":"Gradalis, Inc.","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Vigil (gemogenovatucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 09/01/2017","primary_completion_date":" 09/01/2017","study_txt":" Completion: 09/01/2017","study_completion_date":" 09/01/2017","last_update_posted":"2017-09-27"},{"id":"ff91548c-5e82-427d-8185-38552da3a2a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02639234","created_at":"2021-01-18T12:50:16.993Z","updated_at":"2024-07-02T16:37:19.356Z","phase":"Phase 2","brief_title":"Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02639234","lead_sponsor":"Gradalis, Inc.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK mutation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Vigil (gemogenovatucel-T)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 03/01/2017","primary_completion_date":" 03/01/2017","study_txt":" Completion: 03/01/2017","study_completion_date":" 03/01/2017","last_update_posted":"2017-07-31"}]